|
STRATEC Biomedical AG is a company with worldwide operations that develops and produces analyzer systems and automation systems in the field of in-vitro-diagnostics. As a classic OEM (Original Equipment Manufacturer) supplier, STRATEC produces its systems almost exclusively on behalf of its customers. Alongside the systems themselves, the company also develops system software solutions and software to connect the systems to laboratory software (Middleware). Stratec is also responsible for development documentation, testing and delivering the systems, and supplying spare parts and consumables.〔http://www.stratec.com/share/Gruppe/IR/Financial_Reports/2014/STRATEC_AR_2014_e.pdf〕 == Locations == Since its foundation, the company's headquarters has been in Birkenfeld in Enzkreis district, Gräfenhausen neighborhood. The company also has branches and development and production sites in Berlin, in Burton-upon-Trent, UK, in Newbury Park, USA, in Beringen, Switzerland, and in Cluj-Napoca, Romania.〔http://deutsche-boerse.com/dbg/dispatch/de/kir/dbg_nav/home 〕 History The company was founded in Birkenfeld in 1979. Stratec Biomedical AG was publicly listed (IPO) in 1998. The wholly owned subsidiary Robion AG was founded in Switzerland in 2005 and later renamed as Stratec Biomedical Switzerland AG. Sanguin International, Ltd., UK, was acquired in 2006 and renamed as Stratec Biomedical UK, Ltd. This was followed in 2009 by the acquisition of Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin, now Stratec Molecular GmbH, and of Ballista, Inc., USA, now Stratec Biomedical USA, Inc. in 2010. In November 2010, the company was admitted into the TecDax.() 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Stratec Biomedical Systems」の詳細全文を読む スポンサード リンク
|